MARKET

SLS

SLS

SELLAS LIFE SCIE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.02
-0.26
-2.53%
After Hours: 10.05 +0.03 +0.30% 16:18 09/24 EDT
OPEN
10.10
PREV CLOSE
10.28
HIGH
10.31
LOW
9.99
VOLUME
138.73K
TURNOVER
--
52 WEEK HIGH
19.38
52 WEEK LOW
2.210
MARKET CAP
159.06M
P/E (TTM)
-7.4069
1D
5D
1M
3M
1Y
5Y
BRIEF-Sellas Life Sciences Announces Settlement Of Derivative Litigation
reuters.com · 2d ago
SELLAS Life Sciences Reports Settlement Of Derivative Litigation
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of
Benzinga · 2d ago
SELLAS Life Sciences Announces Settlement of Derivative Litigation
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, to...
GlobeNewswire · 2d ago
Investing in SELLAS Life Sciences Group (NASDAQ:SLS) a year ago would have delivered you a 321% gain
SELLAS Life Sciences Group, Inc. ( NASDAQ:SLS ) shareholders might be concerned after seeing the share price drop 26...
Simply Wall St. · 4d ago
SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, to...
GlobeNewswire · 09/14 12:30
SELLAS Life Sciences Q2 EPS $(0.30) Up From $(0.66) YoY
SELLAS Life Sciences (NASDAQ:SLS) reported quarterly losses of $(0.30) per share. This is a 54.55 percent increase over losses of $(0.66) per share from the same period last year.
Benzinga · 08/12 20:41
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leu...
GlobeNewswire · 08/12 20:22
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021
Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Scien...
GlobeNewswire · 07/28 12:30
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLS. Analyze the recent business situations of SELLAS LIFE SCIE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLS stock price target is 18.50 with a high estimate of 21.00 and a low estimate of 16.50.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 10.70M
% Owned: 67.39%
Shares Outstanding: 15.87M
TypeInstitutionsShares
Increased
13
421.28K
New
5
180.14K
Decreased
5
34.95K
Sold Out
7
221.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Jane Wasman
President/Chief Executive Officer/Director
Angelos Stergiou
Executive Vice President/General Counsel/Secretary
Barbara Wood
Senior Vice President
Dragan Cicic
Chief Accounting Officer/Vice President - Finance/Controller
John Burns
Director
David Scheinberg
Independent Director
Robert Van Nostrand
Independent Director
John Varian
No Data
  • All
  • Financials
  • Insiders
More
About SLS
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.